Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study

BACKGROUND: Giant cell tumor of the bone (GCTB) is classified as an intermediate, locally aggressive but rarely metastasizing tumor. The mainstay of treatment for the treatment of GCTB had been the surgical removal until an anti- receptor activator of nuclear factor-kappa B ligands (RANKL) antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Akihiko, Tsuchiya, Hiroyuki, Ishii, Takeshi, Nishida, Yoshihiro, Abe, Satoshi, Matsumine, Akihiko, Kawai, Akira, Yoshimura, Kenichi, Ueda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957292/
https://www.ncbi.nlm.nih.gov/pubmed/27448567
http://dx.doi.org/10.1186/s12891-016-1163-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957292/
https://www.ncbi.nlm.nih.gov/pubmed/27448567
http://dx.doi.org/10.1186/s12891-016-1163-z

Ejemplares similares